Advancing the Future of Precision Oncology.
Odimma Therapeutics presented its personalized cancer immunotherapy platform at the 5th Neoantigen Summit Europe, held in Amsterdam in April 2022.
The company shared its innovative approach to neoantigen-based immunotherapy with leading scientists, biotechnology companies and industry experts specializing in precision oncology.
The summit provided an important opportunity to highlight Odimma’s vision of harnessing the patient’s own immune system to target tumor-specific neoantigens, reinforcing the company’s commitment to advancing next-generation personalized cancer therapies through scientific innovation and collaboration.
